VIDEO: Pharmacologic and nonpharmacologic development for myeloproliferative neoplasms
Click Here to Manage Email Alerts
Srinivas K. Tantravahi, MBBS, MRCP(UK), spoke with Healio about both nonpharmacologic interventions and pharmacologic developments for patients with myeloproliferative neoplasms.
The summaries of the current data in the field that Tantravahi, hematologist with University of Utah Health and Huntsman Cancer Institute, discussed were presented at the 14th International Congress on Myeloproliferative Neoplasms.
Tantravahi said Angela G. Fleischman, MD, associate professor of hematology/oncology at University of California, Irvine, highlighted interventions to help patient quality of life and is currently enrolling patients in a pilot study.
He then highlighted a presentation on the combination approach for the treatment of myelofibrosis.
“Overall, it’s sort of an exciting time in terms of drug development for [myeloproliferative neoplasms] and also using other nonpharmacologic approaches,” Tantravahi said.
References:
- Fleischman AG. Studies on the MPN microenvironment. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
- Pemmaraju N. Combining novel agents for treating myelofibrosis. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
Collapse
Healio Interviews
Click Here to Manage Email Alerts